page_title: Hospira
section_title: History
hierarchical_section_title: Hospira / History
caption_attribution_description: English: Hospira headquarters
context_page_description: Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
  Worldwide sales in 2014 were approximately $4.5 billion. Current results are now part of Pfizer's consolidated statements.
context_section_description: In January 2004, Abbott announced it was spinning off its hospital products division.
  Hospira's name was picked by employee vote. The name is derived from the words hospital, spirit, inspire and the Latin word "spero," which means "hope." Hospira became an independent company on May 3, 2004, with 14,000 employees, 14 manufacturing sites and an estimated $2.5 billion in annual sales.
  In 2007, Hospira purchased Mayne Pharma Ltd., an Australian-based specialty injectable pharmaceuticals company, for $2.1 billion. 
  In 2009, Hospira acquired the biotechnology business from Pliva-Croatia, the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million, and TheraDoc, a clinical informatics company that develops hospital surveillance systems, in 2009. In 2010, Hospira acquired Javelin Pharmaceuticals, Inc., maker of post-operative pain management drug Dyloject, for approximately $145 million. 
  In 2011, Hospira's board chose Mike Ball, formerly president of Allergan, as Hospira's new CEO. Ball became CEO in March 2011. Hospira named John Staley its non-executive chairman with the retirement of former executive chairman Christopher Begley in January 2012. Begley had announced his retirement as Hospira's chief executive in August 2010, but had remained as executive chairman.
  In 2015, Pfizer signed an agreement to acquire Hospira. The roughly $17 billion acquisition was completed in September, 2015. A year later Pfizer sold the medical devices portion of Hospira to ICU Medical for roughly $900 million in cash, stock, and other consideration.
caption: Hospira corporate headquarters in Lake Forest, Illinois
exif: {"Image SubfileType": "Full-resolution Image", "Image ImageWidth": "4500", "Image ImageLength": "3000", "Image BitsPerSample": "[8, 8, 8]", "Image Compression": "Uncompressed", "Image PhotometricInterpretation": "2", "Image Make": "Canon", "Image Model": "Canon EOS-1Ds Mark II", "Image StripOffsets": "35762", "Image Orientation": "Horizontal (normal)", "Image SamplesPerPixel": "3", "Image RowsPerStrip": "3000", "Image StripByteCounts": "40500000", "Image XResolution": "300", "Image YResolution": "300", "Image PlanarConfiguration": "1", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "Adobe Photoshop CS2 Macintosh", "Image DateTime": "2006:06:22 12:15:51", "Image IPTC/NAA": "[469893120, 33554944]", "Image Tag 0x8649": "[]"}